Results 21 to 30 of about 194,477 (264)

Ondansetron for irritable bowel syndrome with diarrhoea: randomised controlled trial

Efficacy and Mechanism Evaluation, 2023
Background Irritable bowel syndrome with diarrhoea is characterised by frequent, loose or watery stools with associated urgency, resulting in marked reduction of quality of life. Ondansetron, a 5-hydroxytryptamine-3 receptor antagonist, has been shown to
David Gunn, Rabia Topan, Ron Fried, Ivana Holloway, Richard Brindle, Suzanne Hartley, Lorna Barnard, Maura Corsetti, S Mark Scott, Adam Farmer, Ayesha Akbar, Maria Eugenicos, Nigel Trudgill, Kapil Kapur, John McLaughlin, David S Sanders, Arvind Ramadas, Peter Whorwell, Lesley Houghton, Phil G Dinning, Qasim Aziz, Alexander C Ford, Amanda Farrin, Robin Spiller   +23 more
doaj   +1 more source

A randomised controlled trial of an Intervention to Improve Compliance with the ARRIVE guidelines (IICARus)

Research Integrity and Peer Review, 2019
Background The ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines are widely endorsed but compliance is limited. We sought to determine whether journal-requested completion of an ARRIVE checklist improves full compliance with the ...
Kaitlyn Hair, Malcolm R. Macleod, Emily S. Sena, on behalf of the IICARus Collaboration   +3 more
doaj   +1 more source

Is the randomised controlled trial the best?

South African Journal of Obstetrics and Gynaecology, 2014
Different study formats are preferred for different research objectives. Randomised controlled trials (RCTs) have a greater ability to test efficacy than other methods, but RCTs can have many limitations. These limitations should be explored, assessed and exposed.
openaire   +2 more sources

Trial of Acute Femoral Fracture Fixation (TrAFFix): study protocol for a randomised controlled feasibility trial

Trials, 2017
Background Distal femoral fractures are a source of considerable morbidity and best treatment is currently uncertain. The Trial of Acute Femoral Fracture Fixation (TrAFFix) is a randomised, parallel-group feasibility study designed to inform the design ...
Xavier L. Griffin, Matthew L. Costa, Juul Achten, Melina Dritsaki, Janis Baird, Nicholas Parsons   +5 more
doaj   +1 more source

A longitudinal assessment of trial protocols approved by research ethics committees: The Adherance to SPIrit REcommendations in the UK (ASPIRE-UK) study

Trials, 2022
Background To assess the quality of reporting of RCT protocols approved by UK research ethics committees before and after the publication of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guideline.
Benjamin Speich, Ayodele Odutayo, Nicholas Peckham, Alexander Ooms, Jamie R. Stokes, Ramon Saccilotto, Dmitry Gryaznov, Belinda von Niederhäusern, Bethan Copsey, Douglas G. Altman, Matthias Briel, Sally Hopewell   +11 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

Enteral lactoferrin to prevent infection for very preterm infants: the ELFIN RCT

Health Technology Assessment, 2018
Background: Infections acquired in hospital are an important cause of morbidity and mortality in very preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an antimicrobial ...
James Griffiths, Paula Jenkins, Monika Vargova, Ursula Bowler, Edmund Juszczak, Andrew King, Louise Linsell, David Murray, Christopher Partlett, Mehali Patel, Janet Berrington, Nicholas Embleton, Jon Dorling, Paul T Heath, William McGuire, Sam Oddie   +15 more
doaj   +1 more source

The SMILES trial: an important first step

BMC Medicine, 2018
The SMILES trial was the first intervention study to test dietary improvement as a treatment strategy for depression. Molendijk et al. propose that expectation bias and difficulties with blinding might account for the large effect size.
Felice N. Jacka, Adrienne O’Neil, Catherine Itsiopoulos, Rachelle Opie, Sue Cotton, Mohammadreza Mohebbi, David Castle, Sarah Dash, Cathrine Mihalopoulos, Mary Lou Chatterton, Laima Brazionis, Olivia M. Dean, Allison Hodge, Michael Berk   +13 more
doaj   +1 more source

Randomised controlled trials are important

BMJ, 1999
EDITOR—Cranberg's arguments against controlled trials and in favour of historical controls supported by data on matching for known risk factors are seriously flawed.1 There are at least four fallacies. Firstly, the matching procedures …
openaire   +3 more sources

Therapeutic Apheresis in Nigeria: A Multi‐Center Summary of Abstracts From the Inaugural Nigerian Society for Apheresis Scientific Meeting

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye, Chimezie Okwuonu, Evelyn Idam, Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Zinnah Aloziem, Blossom Amamchukwu, Patience Elimia, Mkpoikanabasi Obot‐Obot, Henry Mbakwe, Praises Maduagwuna, Olatunji Akinrodoye, Chiamaka Anyanwu, Benjamin Anyanwu, Adedamola Akinsiku, Oluwatoyin A. Akinsiku, Muzamil O. Hassan, Fatiu A. Arogundade, Olalekan E. Ojo, Homayemem Weli, Jesupelumi Adenihun, Aderemi Adelaja, Ebun Bamgboye, Olalekan Olatise, Ade E. Faponle, Ayoola Odeyemi, Michael Muoka, Stephen Asaolu, Qudrat Busari, Blessing Dawudu, Michael Naiyeju, Rasheed A. Balogun   +33 more
wiley   +1 more source